Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.66 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.66 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.66 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.66 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12434450 | 0.89 | KCNK3 (0.73) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL12434091 | 0.86 | KCNK3 (0.67) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL12434454 | 0.86 | KCNK3 (0.81) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL16250691 | 0.85 | NPC1 (0.62) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL16234809 | 0.82 | NPC1 (0.58) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL16234810 | 0.82 | NPC1 (0.58) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL12434401 | 0.82 | KCNK3 (0.62) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL12434410 | 0.82 | KCNA5 (0.62) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL6482880 | 0.81 | NPC1 (0.57) | KCNK3KCNK5KCNA5KCNK17KCNK9 | |
| SCHEMBL12434419 | 0.81 | KCNK3 (0.66) | KCNK3KCNK5KCNA5KCNK17KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438045-B1 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2016-10-05 | — | — | EP | claimed |
| US-9056833-B2 | Crystalline phases of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-06-16 | — | — | US | claimed |
| EP-2438045-A2 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | Sanofi-Aventis Deutschland GmbH (DE) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139585-A2 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-12-09 | — | — | WO | claimed |
| EP-1605976-B1 | PHENYLCARBOXYL ACID AMIDES AND IK r CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-02-24 | — | — | EP | claimed |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-17 | — | — | US | claimed |
| EP-2438045-B1 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-9056833-B2 | Crystalline phases of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-9056833-B2 | Crystalline phases of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| WO-2014183221-A1 | RESVERATROL ANALOGS AND THERAPEUTIC USES THEREOF | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2014-11-20 | — | — | WO | disclosed |
| CN-102459181-B | Crystalline phases of 2' - { [2- (4-methoxy-phenyl) -acetylamino ] -methyl } -biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl) -amide | SANOFI AVENTIS DEUTSCHLAND | 2014-05-07 | — | — | CN | disclosed |
| CN-102459181-A | Crystalline phases of 2' - { [2- (4-methoxy-phenyl) -acetylamino ] -methyl } -biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl) -amide | SANOFI AVENTIS DEUTSCHLAND | 2012-05-16 | — | — | CN | disclosed |
| EP-2438045-A2 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | Sanofi-Aventis Deutschland GmbH (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139585-A2 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | KCNH2, KCNJ2, KCNH1 | KCNK3 33/4885KCNK5 14/4885KCNA5 6/4885 |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | SCN5A, KCNH1, KCNA5 | KCNK3 84/4885KCNK5 16/4885KCNA5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.